IL13RA2 and glioblastoma: This unique gene expression pattern led to CTA, such as MAGE, NYESO, IL13Rα2 (77, 78), being considered prime targets for antigen-specific immunotherapy and CTA are targets of ongoing clinical trials in glioblastoma (e.g., NCT02208362; www.clinicaltrials.gov).